JP2017533964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533964A5 JP2017533964A5 JP2017543338A JP2017543338A JP2017533964A5 JP 2017533964 A5 JP2017533964 A5 JP 2017533964A5 JP 2017543338 A JP2017543338 A JP 2017543338A JP 2017543338 A JP2017543338 A JP 2017543338A JP 2017533964 A5 JP2017533964 A5 JP 2017533964A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- compound
- day
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 9
- 102000004132 Ornithine aminotransferases Human genes 0.000 claims description 6
- 108090000691 Ornithine aminotransferases Proteins 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 125000000656 azaniumyl group Chemical group [H][N+]([H])([H])[*] 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 239000002585 base Substances 0.000 claims 2
- 239000003513 alkali Substances 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 27
- 0 *C(CC(C1)C(O)=O)C1=C(*)* Chemical compound *C(CC(C1)C(O)=O)C1=C(*)* 0.000 description 7
- 239000006143 cell culture medium Substances 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- -1 carboxylate salt Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076980P | 2014-11-07 | 2014-11-07 | |
| US62/076,980 | 2014-11-07 | ||
| PCT/US2015/059738 WO2016073983A2 (en) | 2014-11-07 | 2015-11-09 | Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533964A JP2017533964A (ja) | 2017-11-16 |
| JP2017533964A5 true JP2017533964A5 (enExample) | 2018-12-06 |
| JP6867949B2 JP6867949B2 (ja) | 2021-05-12 |
Family
ID=55910047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543338A Active JP6867949B2 (ja) | 2014-11-07 | 2015-11-09 | 肝細胞癌を治療する為のｇａｂａ類似体を用いたオルニチンアミノ基転移酵素の阻害方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9603820B2 (enExample) |
| EP (1) | EP3215144B1 (enExample) |
| JP (1) | JP6867949B2 (enExample) |
| AU (1) | AU2015342801A1 (enExample) |
| CA (1) | CA2966642C (enExample) |
| ES (1) | ES2882126T3 (enExample) |
| IL (1) | IL252042B (enExample) |
| MX (1) | MX2017006022A (enExample) |
| WO (1) | WO2016073983A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112218628A (zh) * | 2018-03-29 | 2021-01-12 | 奥维德医疗公司 | (1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗眼紊乱中的用途 |
| US10822301B2 (en) | 2018-04-12 | 2020-11-03 | Northwestern University | 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase |
| US10836708B2 (en) * | 2018-05-25 | 2020-11-17 | Northwestern University | Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid |
| JP7387179B2 (ja) | 2018-06-07 | 2023-11-28 | オービッド・セラピューティクス・インコーポレイテッド | 発達障害の処置における（ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペンタ－１－エン－１－カルボン酸および関連化合物、（１ｓ，３ｓ）－３－アミノ－４－（ジフルオロメチリデン）シクロペンタン－１－カルボン酸ならびにビガバトリンの使用 |
| WO2020176511A1 (en) * | 2019-02-25 | 2020-09-03 | Northwestern University | Analogs of 3-amino-4-(propan-2-ylidene) cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity |
| WO2020206234A1 (en) * | 2019-04-03 | 2020-10-08 | Northwestern University | 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase |
| US11993569B2 (en) | 2020-01-23 | 2024-05-28 | Northwestern University | 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases |
| CN117321025A (zh) * | 2021-03-03 | 2023-12-29 | 西北大学 | 作为人鸟氨酸氨基转移酶的选择性灭活剂的(s)-3-氨基-4,4-二卤代环戊-1-烯甲酸 |
| JP2024515306A (ja) * | 2021-04-20 | 2024-04-08 | バイスクルテクス・リミテッド | Ｐ－セレクチンに特異的な二環式ペプチドリガンド |
| AU2022331568A1 (en) * | 2021-08-19 | 2024-03-14 | N1 Life, Inc. | Taxol conjugate compounds, pharmaceutical compositions comprising the same, and methods for their use |
| WO2024196851A1 (en) * | 2023-03-17 | 2024-09-26 | Northwestern University | Bicyclic compounds as inactivators of oat and gaba-at |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| IL177609A (en) | 2006-08-21 | 2015-11-30 | Yaron Ilan | Use of gobacoline or its analogue to produce a drug to treat liver carcinoma |
-
2015
- 2015-11-09 CA CA2966642A patent/CA2966642C/en active Active
- 2015-11-09 MX MX2017006022A patent/MX2017006022A/es unknown
- 2015-11-09 AU AU2015342801A patent/AU2015342801A1/en not_active Abandoned
- 2015-11-09 WO PCT/US2015/059738 patent/WO2016073983A2/en not_active Ceased
- 2015-11-09 EP EP15856956.6A patent/EP3215144B1/en active Active
- 2015-11-09 JP JP2017543338A patent/JP6867949B2/ja active Active
- 2015-11-09 US US14/936,153 patent/US9603820B2/en active Active
- 2015-11-09 ES ES15856956T patent/ES2882126T3/es active Active
-
2017
- 2017-04-30 IL IL252042A patent/IL252042B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533964A5 (enExample) | ||
| JP3778516B2 (ja) | 新規なアリールプロピオン酸誘導体、その製造方法及び鎮痛薬としてのその用途 | |
| EP1991522B1 (en) | Deuterated catecholamine derivatives and medicaments comprising said compounds | |
| EA201101671A1 (ru) | Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина | |
| JP2010526827A5 (enExample) | ||
| MX2010010647A (es) | Proceso para preparar formulaciones de dabigatran para administracion oral. | |
| RU2005109913A (ru) | Азабициклоалкильные эфиры и их применение в качестве агонистов альфа7-nachr | |
| JP2015536940A (ja) | 抗ウイルス性ホスホネート類似体及びその製造方法 | |
| HRP20170903T1 (hr) | Supstituirani pirolidin-2-karboksamidi | |
| ES2625329T3 (es) | Agentes bloqueantes neuromusculares asimétricos reversibles de duración ultra-corta, corta o intermedia | |
| HRP20130092T4 (hr) | Karbamoil-cikloheksani za lijeäśenje akutne manije | |
| MX2011009709A (es) | Compuestos para el tratamiento de la inflamacion y del dolor. | |
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| JP2013519653A5 (enExample) | ||
| HRP20151138T1 (hr) | Dihidroetorfini i njihovo pripremanje | |
| JP2012144537A5 (enExample) | ||
| JP2017503753A5 (enExample) | ||
| JP2012510985A5 (enExample) | ||
| RU2008110644A (ru) | Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств | |
| EP2150550A4 (en) | NEW CARBAMOYLOXY-ARYL-ALKAN-ARYLPIPERAZIN COMPOUND, PHARMACEUTICAL COMPOSITIONS WITH THE COMPOUND AND METHOD FOR THE TREATMENT OF PAIN, FEAR STATES AND DEPRESSION BY MEANS OF ADMINISTRATION OF THE COMPOUND | |
| JP2010526826A5 (enExample) | ||
| RU2007138582A (ru) | Пероральные дозированные формы производных гемцитабина | |
| MX2010003594A (es) | Formas cristalinas de sal sodica de dmxaa. | |
| DE10261807A1 (de) | Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel | |
| JPH06511231A (ja) | ２−（ピロリジニル−１−メチル）−ピペリジン誘導体およびκ受容体アゴニストとしてのその使用 |